|
著者: E Fontas, F van Leth, C A Sabin, N Friis-Møller, M Rickenbach, A d'Arminio Monforte, O Kirk, M Dupon, L Morfeldt, S Mateu, K Petoumenos, W El-Sadr, S de Wit, J D Lundgren, C Pradier, P Reiss, D:A:D Study Group
雑誌名: J Infect Dis. 2004 Mar 15;189(6):1056-74. doi: 10.1086/381783. Epub 2004 Mar 2.
Abstract/Text
Levels of triglycerides (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-c), and high-density lipoprotein cholesterol (HDL-c), as well as the TC:HDL-c ratio, were compared in patients receiving different antiretroviral therapy regimens. Patients receiving first-line regimens including protease inhibitors (PIs) had higher TC and TG levels and TC : HDL-c ratios than did antiretroviral-naive patients; patients receiving 2 PIs had higher levels of each lipid. Ritonavir-containing regimens were associated with higher TC and TG levels and TC : HDL-c ratios than were indinavir-containing regimens; however, receipt of nelfinavir was associated with reduced risk of lower HDL-c levels, and receipt of saquinavir was associated with lower TC : HDL-c ratios. Patients receiving nonnucleoside reverse-transcriptase inhibitors had higher levels of TC and LDL-c than did antiretroviral-naive patients, although the risk of having lower HDL-c levels was lower than that in patients receiving a single PI. Efavirenz was associated with higher levels of TC and TG than was nevirapine.
PMID 14999610 J Infect Dis. 2004 Mar 15;189(6):1056-74. doi: 10.1086/381783. Epub 2004 Mar 2.
|